Enzo Biochem Income Statement 2024-2009 | ENZ

Brief overview of income trends at Enzo Biochem

The figures are compared over a five-year interval. According to figures from Enzo Biochem, revenue changed from 81.2 million dollars to 31.9 million dollars over five years. Overall revenue changed by −60.7%, equal to an annualized rate of about −17%. Revenue ended the period on a sustained downward trend.

The five-year change in gross profit reached +157.3%: from 5.7 million dollars to 14.6 million dollars. Direct costs grew more slowly than revenue and improved the economics of sales. The gross margin was 7% at the start and 45.9% at the end. The margin shift points to a more favorable sales-and-cost structure.

EBITDA was 3.9 million dollars at the beginning and −11.1 million dollars at the end of the period (−382.5%). EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of 4.8% and −34.8%. Operating return per unit of revenue declined.

The final result was 2.5 million dollars initially and −26.1 million dollars in the final year. The emergence of a loss requires close attention to costs and the operating model.

The five-year change in capitalization reached −99.9%: from $101 million to $57.5 thousand. Lower capitalization reflects weaker investor expectations.

Financial takeaway

The indicators point to a weaker financial profile. The positive side is supported by improving gross profitability. The overall view is constrained by declining net profitability, a weaker market valuation and limited revenue growth. The key question is whether sales can be converted into sustainable profit.